Lung cancer in practice

 

Reference list

 

Dhillon T, Seckl MJ. A review of small cell lung cancer treatments. Lung cancer in practice 2008; 5.3: 1–5.

 

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.

 

2. Simon GR, Wagner H, American College of Chest Physicians. Small cell lung cancer. Chest 2003; 123 (Suppl 1): S259–S271.

 

3. Lee HW, Han JH, Kim JH et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008; 59: 95–104.

 

4. Bremnes RM, Sundstrom S, Aasebż U et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003; 39: 303–313.

 

5. Ruotsalainen T, Joensuu H, Mattson K, Salven P. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev, 2002; 11: 1492–1495.

 

6. Kurup, A, Hanna NH. Treatment of small cell lung cancer. Crit Rev Oncol Hematol 2004; 52: 117–126.

 

7. Perry MC, Eaton WL, Propert KJ et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316: 912–918.

 

8. Johnson DH, Bass D, Einhorn LH et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 1993; 11: 1223–1229.

 

9. Osterlind K, Hansen HH, Hansen HS et al. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br J Cancer 1986; 54: 7–17.

 

10. Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992. 327: 1618–1624.

 

11. Sundstrom S, Bremnes RM, Kaasa S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20: 4665–4672.

 

12. Ettinger DS, Berkey BA, Abrams RA et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol  2005; 23: 4991–4998.

 

13. Fried DB, Morris DE, Poole C et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22: 4837–4845.

 

14. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999.  341: 476-484.

 

15. Pujol JL, Daures JP, Riviere A et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 93: 300–308.

 

16. Okamoto H, Watanabe K, Kunikane H et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer  2007; 97: 162–169.

 

17. Slotman B, Faivre-Finn C, Kramer G et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357: 664–672.

 

18. Noda K, Nishiwaki Y, Kawahara M. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85–91.

 

19. Johnson BE, Bridges JD, Sobczeck M. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14: 806–813.

 

20. O'Brien ME, Ciuleanu TE, Tsekov H et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441–5447.

 

21. Micke P, Basrai M, Faldum A et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003; 9: 188–194.

 

22. Johnson BE, Fischer T, Fischer B. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; (16 Pt 1) 9: 5880–5887.

 

23. Schneider B, Gadgeel S, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17089


24. Pandya K, Levy D, Hidalgo M, et al. A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report (2005) Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 7005

 

25. Khanzada UK, Pardo OE, Meier C et al. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 2006; 25: 877-887

 

26. Hanbali AS, Urbaez Duran E, Wang D et al. The use of statins and the effect on survival in patients with small cell lung cancer. Journal of Clinical Oncology, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 24, No 18S (June 20 Supplement), 2006.

 

27. Lee SM, Woll PJ, James LE et al. A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC). J Thor Oncol 2007.2:S306­S307 (suppl 4; abstr PRS-04).

 

28. Hasegawa Y, Takanashi S, Okudera K et al. Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. Intern Med 2005; 44: 26–34.

 

29. Patton JF, Spigel DR, Greco FA et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No.18S (June 20 Supplement), 2006: 7085.

 

30. Higashiyama M, Doi O, Kodama K et al. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res 15: 503–505.

 

31. Guensberg P, Wacheck V, Lucas T et al. Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy 2002. 48: 189–195.

 

32. Ziegler A, Luedke GH, Fabbro D et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997; 89: 1027–1036.

 

33. Rudin CM, Kozloff M, Hoffman PC. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22: 1110–1117.

 

34. Pardo OE, Wellbrock C, Khanzada UK, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. Embo J 2006; 25: 3078–3088.

 

35. Pardo OE, Lesay, A, Arcaro A et al. Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol 2003; 23: 7600–7610.

 

 

Published by Hayward Medical Communications

www.hayward.co.uk